Skip to content

Muscle & performance

Gonadorelin

GnRH · LHRH · Factrel (brand) · Luteinising hormone-releasing hormone

Approved for another indicationProhibited in sportReviewed 16 Aug 2026

Gonadorelin is not an analogue of anything. It is the identical ten-amino-acid sequence of human gonadotropin-releasing hormone, the signal the hypothalamus sends to the pituitary to release LH and FSH. It has held FDA approval as a diagnostic agent — used to test whether a pituitary responds — and it is approved in veterinary medicine for reproductive management.

It has become widely used for a purpose it was never approved or studied for: maintaining testicular function during testosterone replacement therapy. The reasoning is straightforward. Exogenous testosterone suppresses the body's own LH signal, the testes shrink and stop producing sperm, and supplying a GnRH pulse should keep that pathway alive. Many clinicians prescribe it for exactly this, having moved away from hCG when that became harder to obtain.

The rationale is sound and the evidence for it in this specific use is thin. What has actually been studied is hCG, which acts further down the chain at the testis. Gonadorelin acts at the pituitary, which means it can only work if the pituitary is still responsive. There is a further complication that matters here: continuous exposure to GnRH suppresses the axis instead of stimulating it. That is not a theoretical risk; it is the established mechanism of prostate cancer treatment.

How it works

Gonadorelin binds GnRH receptors on pituitary gonadotroph cells, causing release of LH and FSH. LH drives testosterone production in the testis, and FSH drives sperm production. It is the natural signal, not a modified version of it.

Pulsatility is everything with this molecule, and it is the reason two opposite clinical uses exist. Delivered in pulses, as the hypothalamus does naturally, it stimulates the axis. Delivered continuously, it downregulates the receptors and shuts the axis down. That is precisely how GnRH agonists achieve chemical castration in prostate cancer treatment.

Its half-life is a few minutes. Which is what allows intermittent injection to approximate a pulse. It is also why the interval between injections is the variable that decides whether you are stimulating or suppressing, and why frequent dosing is not obviously the cautious choice.

Compared with hCG, which mimics LH directly at the testis, gonadorelin acts one step earlier. That preserves more of the natural feedback loop in principle, and it also means it does nothing if the pituitary itself is unresponsive.

Regulatory status — United States

Approved by the FDA as a diagnostic agent for evaluating pituitary gonadotropin function, and approved in veterinary reproductive medicine. Not approved for use alongside testosterone replacement therapy, though it is commonly prescribed off-label and compounded for that purpose. Material sold as a research chemical is not a compounded prescription product.

Last reviewed 16 Aug 2026. Regulatory positions in this category change frequently; we date this line so you can see how current it is.

What it is studied for

Each entry states the evidence behind it. We do not rank indications by effectiveness — for most compounds here, that would be a claim nobody can support.

Testing pituitary gonadotropin function

Clinical trial

The approved human use.

EvidenceApproved as a diagnostic agent, with LH measured after a single dose to establish whether the pituitary responds.

Maintaining testicular function during testosterone therapy

Community practice

The common off-label use, and the reason it is bought.

EvidenceNo controlled trial has studied gonadorelin for this. The evidence in this setting is for hCG, a different molecule acting at a different point in the cascade.

Restoring fertility after anabolic steroid use

Community practice

Described in the same context.

EvidenceRecovery protocols have been studied with hCG and selective oestrogen receptor modulators. Gonadorelin has not been studied for this purpose.

Identity and clearance

Molecule

Class
Gonadotropin-releasing hormone, identical to the human sequence
Molecular weight
1182.3 Da
Length
10 amino acids

Sequence

Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2

Pharmacokinetics

Clinical trial
Peak0.3 h
Half-life0.1 h
Substantially cleared0.5 h
100%50%25%0%half-life 0hdose0h0h0h1h
Modelled from the half-life above, assuming first-order elimination. Illustrative rather than measured — it shows the shape of clearance, not a prediction for any individual.

A half-life of around four minutes. The LH response peaks within about 30 minutes and is over within hours. That is why dosing frequency — not dose size — is the variable that matters here.

Dose protocols reported in sources

Displayed for reference only. Every row says where it came from, and a trial protocol and a community convention are not the same kind of information. None of this is fed into the calculator, and none of it is a recommendation.

Dose protocols reported in sources, with the source of each.
GoalDoseFrequencyRouteUnits, 2 mg vialSourceStart this protocol
Diagnostic test, the approved use100 mcgA single dose, onceSubcutaneous100 mcg with LH and FSH sampled over the following two hours. This is a test of pituitary responsiveness, not a treatment.10 uClinical trialStart this
Commonly prescribed alongside testosterone therapy100 mcg – 200 mcgTwo to three times weekly, or on the same schedule as testosteroneSubcutaneousThe figures most often described in compounded prescriptions and community practice. No trial has established either the dose or the interval for this use, and the interval is the variable that determines whether the axis is stimulated or suppressed.10–20 uCommunity practiceStart this

Start this copies a row into a protocol of your own, which you can then edit. Where a source gave a dose range or an ambiguous frequency, those fields arrive empty — we will not pick a number on your behalf.

CheckRows marked community practice describe what people commonly do, drawn from public discussion. They are not derived from any trial and are not evidence that a dose is safe or effective.

Calculator

Work out what to draw

Pre-filled with a 2 mg vial as a worked example. These are not recommended values — change them to match the vial in front of you.

Dose unit
Your syringe
010203040506070809010010 units0.1 mL

Draw to 10 units on a 1 mL U-100 syringe. That is 0.1 mL, containing 100 mcg of Gonadorelin.

Concentration1mg / mL
Volume drawn0.1mL
Doses per vial20doses
Per unit10mcg / unit

10 units sits exactly on a printed line.

Bioalmanac performs arithmetic on values you enter. It does not recommend doses, schedules or compounds, and nothing here is medical advice. Confirm every calculation against your vial and syringe before drawing, and speak with a licensed healthcare provider.

Open this calculation in the full calculator

Units, concentration, bacteriostatic water — the glossary defines the vocabulary, and a unit is not a fixed volume.

Safety

Reported effects

  • Generally well tolerated in diagnostic useClinical trial

    Established

    The approved use is a single dose. That tolerability record does not extend to repeated dosing over months.

  • Headache, flushing and nauseaClinical trial

    Occasionally reported

  • Injection site reactionsCommunity practice

    Commonly reported

  • Suppression of the axis with too-frequent dosingPublished review

    Mechanistically established

    The opposite of the intended effect, and not a rare idiosyncrasy. Continuous GnRH exposure downregulating the receptor is the basis of prostate cancer treatment. It would present as worsening rather than improving testicular function.

  • Whether it preserves fertility as intendedCommunity practice

    Unstudied

    No trial has measured sperm parameters or testicular volume on gonadorelin alongside testosterone therapy. The rationale is mechanistic.

When to stop

  • Testicular shrinkage that continues or worsens. That is the outcome it is meant to prevent, and a sign the schedule may be suppressing rather than stimulating.
  • Falling libido or morning erections beyond what the testosterone protocol explains.
  • Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.
  • Persistent headache, flushing or nausea after dosing.

Interactions and situations that need care

  • Hormone-sensitive cancer, including prostate and breastAvoid

    Stimulating the axis raises testosterone and oestrogen, which are the growth signals these cancers depend on. The irony that continuous GnRH is used to treat prostate cancer does not make intermittent GnRH safe there. It makes the dosing interval the difference between two opposite effects.

  • Using it in place of medical supervision on testosterone therapyUse caution

    Testosterone therapy needs monitoring of haematocrit, oestradiol, PSA and lipids regardless of what else is added. Adding an unstudied peptide to an unmonitored protocol compounds the problem rather than mitigating it.

  • Pregnancy and breastfeedingAvoid

    Manipulating the reproductive axis during pregnancy has no justification and no safety data.

  • Competing in a tested sportAvoid

    Gonadotrophin-releasing factors are prohibited for male athletes at all times under WADA's S2 category, alongside hCG and LH.

SportProhibited by the World Anti-Doping Agency under S2: Peptide Hormones, Growth Factors, Related Substances, gonadotrophin-releasing factors, at all times, for male athletes. Gonadotrophin-releasing factors are prohibited for males at all times. hCG and LH are named in the same section.

What to expect

HonestlyThere is no human efficacy data for this compound, so there is no evidence-based timeline to give. Any site publishing a week-by-week schedule of expected effects has invented it.

  • It reliably produces an LH rise from a single dose. That is established and it is the approved diagnostic use.
  • Whether it preserves testicular function during testosterone therapy has never been studied. The evidence in that setting belongs to hCG, a different molecule acting at a different point.
  • Dosing frequency decides the direction of the effect. Too frequent moves toward the continuous exposure that suppresses the axis, so more is not safer here.
  • It only works if your pituitary responds. hCG acts directly at the testis and does not have that requirement.
  • It is prescribed off-label by many clinicians. That is a reasonable clinical judgement about a sound rationale, not a substitute for trial evidence.

Storage and handling

Freeze-dried powder
Refrigerated at 2–8 °C, protected from light.
After mixing
Refrigerated at 2–8 °C. Do not freeze once mixed. Bacteriostatic water is preferable given the multi-week dosing pattern.
Long-term, frozen
Unopened powder is stable at −20 °C or colder.

Printable one-pagerHow to reconstitute a vial, step by step

With other peptides

  • HCGcaution

    Both are used to keep the gonadal axis running during testosterone therapy, at different points. This acts on the pituitary; hCG bypasses it and acts on the testes. Using both is redundant rather than additive.

  • Prescribed alongside testosterone to preserve the pituitary signal it suppresses. Which of this and hCG suits depends on where the suppression sits, which is a clinical question.

Check this against a whole stack

Checking your vial

Research chemicals carry no manufacturing standard, so what the vial looks like is often the only quality signal available before you use it. More on assessing quality and COAs.

  • White cake, clear solution

    Standard for a short peptide.

  • Collapsed cake or cloudy solution

    Heat damage or degradation. Do not use it.

Questions

Is gonadorelin better than hCG for preserving fertility on TRT?
Nobody knows, because it has not been studied for that. hCG has the evidence. The argument for gonadorelin is that acting at the pituitary preserves more of the natural loop. A reasonable mechanistic case, and a case, not a finding.
How often should I inject it?
No trial establishes this, and it is the question that matters most with this compound. Frequency determines whether you stimulate or suppress the axis, because continuous GnRH exposure downregulates the receptor. That makes it a question for a prescriber who can measure the result, not one to resolve by increasing the dose.
Why is a natural hormone only approved as a diagnostic?
Because its four-minute half-life makes it impractical as a treatment. Sustained therapy needs either a pump delivering genuine pulses or a long-acting analogue. The long-acting analogues suppress the axis, which is what they are used for.

References

  1. Gonadorelin as a diagnostic agent for pituitary gonadotropin function

    FDA prescribing information and supporting clinical literature, 2015 · Regulatory labelling based on clinical data

    Humans · 100 mcg, single dose · Single administration with sampling over 2 hours

    Produces a reliable, measurable LH and FSH response, supporting approval as a test of pituitary gonadotroph function. Well tolerated in single-dose use, with headache, flushing and nausea occasionally reported.

  2. Pulsatile versus continuous GnRH exposure: stimulation and desensitisation of the gonadal axis

    Reproductive endocrinology review literature, 2016 · Review

    Humans

    Establishes that pulsatile GnRH stimulates gonadotropin release while continuous exposure downregulates the receptor and suppresses the axis, the mechanistic basis for using GnRH agonists to suppress testosterone in prostate cancer.

  3. Commonly described protocols alongside testosterone therapy

    Bioalmanac editorial summary of public sources and compounded prescribing patterns, 2026 · Not a study

    Records the doses and intervals described in community discussion and in compounded prescriptions. No trial has studied gonadorelin in this setting, and these carry no evidential weight about safety or effect.

Keep this page honest

If something here is wrong, out of date, or missing a source, tell us and we will fix it and say that we did.

Suggest a correction

This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice. No clinician reviews these pages.

Page last updated 16 Aug 2026